Home › NDC Lookup › Ingredients › Ziprasidone Hydrochloride › 65862-0705-60
💊image loading
(from DailyMed)

Ziprasidone Hydrochloride 80 mg Capsule, 60-count — NDC 65862-705-60 (Billing 65862-0705-60)

by Aurobindo Pharma Limited · 60 CAPSULE in 1 BOTTLE

This is a package of 60 capsules of Ziprasidone Hydrochloride 80 mg Capsule from Aurobindo Pharma Limited, marketed since Dec 2016 and currently FDA-listed; retail pharmacies pay about $0.3157 per capsule (NADAC). It is the main listing for this product, which comes in 4 package sizes.

NDC 65862-0705-60
🏷️ FDA NDC (as labeled) 65862-705-60 billing pads the product segment with a zero
This package
Contains60-count Cost per ea$0.3157 NADAC Per package$18.94 / 60 capsules Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.4948/unit · Part D plans $0.5539/unit — full pricing hub ↓
Main listing for product 65862-705 · Also comes in: 80 capsules 65862-705-80 1000 capsules 65862-705-99 2000 capsules 65862-705-22
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 65862-705-60 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
65862 labeler · 705 product · 60 package
Listing certified through
Dec 31, 2026
Billing quantity
60 EA per package
Barcode (UPC-A, from the NDC)
3 6586270560 0
Medicaid fills, this package
16,495 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65862-705-60
Product NDC 65862-705
11-digit billing NDC 65862070560
NCPDP billing unit EA — each (per item)
SPL Set ID fd76cda6-a927-48f4-935c-bc2bb92e1f41
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2016-12-27
Dosage form CAPSULE
Substance ZIPRASIDONE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 59400085100150
GPI class Ziprasidone HCl
GCN Seq No 047568
GCN 13334
HICL code 021974
Ingredient (HICL) Ziprasidone Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H7
Therapeutic class — intermediate (HIC2) Psychoactive Drugs (Continued 1)
HIC3 code H7T
Therapeutic class — specific (HIC3) Antipsychotic,Atypical,Dopamine,Serotonin Antagnst
AHFS code 28:16.08.04
AHFS class Atypical Antipsychotics
FDB label name ZIPRASIDONE HCL 80 MG CAPSULE
FDB brand name Ziprasidone Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 047568
  • GCN: 13334
  • GPI-14 (Medi-Span): 59400085100150
  • HICL (First Databank): 021974
  • AHFS class code: 28:16.08.04
Why two NDCs? The FDA registers this code as 65862-705-60 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65862-0705-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ZIPRASIDONE HCL 80 MG CAPSULE Ingredient Ziprasidone Hcl
📗 Our plain-language guide HelloPharmacist
  • It treats schizophrenia and bipolar I disorder in adults. The capsules are used for ongoing treatment, and the injection is used for sudden agitation in schizophrenia. Your prescri...
  • Take them by mouth with food, since a meal helps your body absorb the medicine. Swallow them whole. Do not open, crush or chew them. Follow your prescriber's schedule.
  • Sleepiness, dizziness, restlessness, tremor or stiffness, nausea and vomiting are common. Be careful with driving or machinery until you know how it affects you. Tell your prescrib...
  • Seek help for fainting, a racing or irregular heartbeat, high fever with stiffness, a new rash, uncontrolled movements, or thoughts of suicide. These can be signs of serious reacti...
📖 Read our full Ziprasidone guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.316 $18.94 / 60 capsules
Medicaid paysCMS SDUD · 12 mo $0.4948 $29.69 / 60 capsules
Medicare drug plans payPart D · Q2 2026 $0.5539 $33.23 / 60 capsules
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.444 $0.303
▼ Down 26% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
65862-0705-60 You're viewing this Main listing 60 CAPSULE in 1 BOTTLE $0.3157 / ea $18.94 2016-12-27 — Active
65862-0705-80 65862-705-80 8 BLISTER PACK in 1 CARTON / 10 CAPSULE in 1 BLISTER PACK — — 2016-12-27 — Active
65862-0705-99 65862-705-99 1000 CAPSULE in 1 BOTTLE — — 2016-12-27 — Active
65862-0705-22 65862-705-22 2000 CAPSULE in 1 BAG — — — — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 60-count package — 60 capsule in 1 bottle.
How does this package differ from NDC 65862-0705-80?
Both are Ziprasidone Hydrochloride 80 mg Capsule — the drug itself is identical. This page's package is the 60-count one, while NDC 65862-0705-80 is the 80 capsules package.
What NDC number is used to bill for this package of Ziprasidone Hydrochloride 80 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ziprasidone 80 mg 00904-6272-08 Major 40 capsules $0.316 AB Availability likely —
ziprasidone 80 mg 16714-0838-01 NorthStar 60 capsules $0.316 AB Availability likely —
Ziprasidone Hydrochloride 80 mg 33342-0147-09 Macleods 60 capsules $0.316 AB Availability likely —
ziprasidone hydrochloride 80 mg 50268-0814-12 AvPAK 20 capsules $0.316 AB Availability likely —
ziprasidone hydrochloride 80 mg 60505-2531-06 Apotex 60 capsules $0.316 AB Availability likely —
Ziprasidone 80 mg 62135-0994-60 Chartwell 60 capsules $0.316 AB Availability likely —
Ziprasidone Hydrochloride 80 mgthis 65862-0705-60 Aurobindo 60 capsules $0.316 — Availability likely —
Ziprasidone Hydrochloride 80 mg 68001-0453-06 BluePoint 60 capsules $0.316 AB Availability likely —
Ziprasidone Hydrochloride 80 mg 68084-0106-09 American 80 capsules $0.316 AB Availability likely —
Geodon 80 mg 00049-0358-60 ROERIG 60 capsules $31.108 AB Availability likely +9755%
Geodon 80 mg 58151-0134-91 Viatris 60 capsules $31.108 AB Availability likely +9755%
Geodon 80 mg 00049-0058-60 ROERIG 60 capsules — AB Discontinued —
ziprasidone 80 mg 55111-0259-01 Dr. 100 capsules — AB FDA listed —
ziprasidone hydrochloride 80 mg 60429-0768-60 Golden 60 capsules — AB FDA listed —
ziprasidone hydrochloride 80 mg 63629-6916-01 Bryant 60 capsules — AB FDA listed —
ziprasidone hydrochloride 80 mg 70518-1604-00 REMEDYREPACK 30 capsules — AB Discontinued —
Ziprasidone Hydrochloride 80 mg 71335-0501-01 Bryant 60 capsules — AB FDA listed —
ziprasidone hydrochloride 80 mg 71335-1508-01 Bryant 60 capsules — AB FDA listed —
ziprasidone hydrochloride 80 mg 42816-0058-01 Pfizer 22160 capsules — — FDA listed —
ziprasidone hydrochloride 80 mg 42816-2004-01 Pfizer 22160 capsules — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2016
On the market since
Dec 2016
📍
2026
Currently FDA-listed
10 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Ziprasidone inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code65862
First marketedDec 2016
Product typeDrug For Further Processing
Portfolio1,464 products on file

More NDCs from Aurobindo Pharma Limited labeler code 65862

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
16.5K
Units reimbursed last 4 qtrs
928.9K
Gross reimbursed last 4 qtrs
$459.6K
Avg / prescription
$27.87
Avg / unit
$0.4948
Latest quarter Q1 2026
3.3KRx
Medicaid pays / ea
$0.4948
gross reimbursed
vs
NADAC / ea
$0.3157
acquisition cost
=
Spread
+$0.1791
+57% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
43% FFS 57% MCO
Fee-for-service · 7,167 Rx Managed care · 9,328 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 15,115 units · 193 per 100k residents WA Idaho: no data reported ID Montana: 1,710 units · 151 per 100k residents MT North Dakota: 960 units · 123 per 100k residents ND Minnesota: 4,805 units · 83.8 per 100k residents MN Wisconsin: 8,281 units · 140 per 100k residents WI Michigan: 22,884 units · 228 per 100k residents MI New York: 66,895 units · 342 per 100k residents NY Vermont: 589 units · 91.0 per 100k residents VT New Hampshire: 1,162 units · 82.9 per 100k residents NH Oregon: 6,344 units · 150 per 100k residents OR Nevada: 17,082 units · 535 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 3,660 units · 114 per 100k residents IA Illinois: 41,922 units · 334 per 100k residents IL Indiana: 44,999 units · 656 per 100k residents IN Ohio: 49,387 units · 419 per 100k residents OH Pennsylvania: 116,798 units · 901 per 100k residents PA New Jersey: 24,867 units · 268 per 100k residents NJ Massachusetts: 3,178 units · 45.4 per 100k residents MA California: 199,147 units · 511 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 720 units · 36.4 per 100k residents NE Missouri: 7,549 units · 122 per 100k residents MO Kentucky: 1,050 units · 23.2 per 100k residents KY West Virginia: 18,538 units · 1,047 per 100k residents WV Virginia: 12,876 units · 148 per 100k residents VA Maryland: 15,875 units · 257 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 34,905 units · 470 per 100k residents AZ New Mexico: no data reported NM Kansas: 1,350 units · 45.9 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 2,903 units · 26.8 per 100k residents NC South Carolina: 1,058 units · 19.7 per 100k residents SC Delaware: 5,340 units · 518 per 100k residents DE Oklahoma: 10,628 units · 262 per 100k residents OK Louisiana: 20,213 units · 442 per 100k residents LA Mississippi: 6,528 units · 222 per 100k residents MS Alabama: 8,172 units · 160 per 100k residents AL Georgia: 4,138 units · 37.5 per 100k residents GA D.C.: no data reported DC Hawaii: 1,396 units · 97.3 per 100k residents HI Texas: 51,714 units · 170 per 100k residents TX Florida: 94,204 units · 417 per 100k residents FL
Units reimbursed · per 100k residents
19.71,047
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 West Virginia 1,047 /100k
2 Pennsylvania 901 /100k
3 Indiana 656 /100k
4 Nevada 535 /100k
5 Delaware 518 /100k
6 California 511 /100k
7 Arizona 470 /100k
8 Louisiana 442 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
60 capsules this page65862-0705-60 16,495 Rx · $459,636
80 capsules65862-0705-80 No Medicaid data
1000 capsules65862-0705-99 No Medicaid data
2000 capsules65862-0705-22 No Medicaid data
Drug total (last 4 qtrs): 16,495 Rx · 928,942 units · $459,636 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 80 capsules (65862-0705-80), 1000 capsules (65862-0705-99), 2000 capsules (65862-0705-22). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65862-0704-60 · Aurobindo 65862-0706-01 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.